Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 5/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160807 | 0.91 | SMN1; SMN2 (0.33) | HRH3SMN1; SMN2GCKALDH1A1MAPT | |
| SCHEMBL5163224 | 0.84 | HRH3 (0.33) | HRH3SMN1; SMN2GCKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL5160056 | 0.81 | HPGDS (0.33) | HRH3SMN1; SMN2OGAHTTTRPV1 | |
| Hydrochloric Acid SCHEMBL5161217 | 0.81 | HPGDS (0.33) | HRH3SMN1; SMN2OGAHTTTRPV1 | |
| SCHEMBL27542566 | 0.80 | TRPV1 (0.41) | HRH3GCKALDH1A1TRPV1POLB | |
| SCHEMBL6178048 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MAPTHTT | |
| SCHEMBL5160587 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MAPTHTT | |
| Hydrochloric Acid SCHEMBL5160519 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MAPTHTT | |
| SCHEMBL5162229 | 0.75 | HRH3 (0.33) | HRH3SMN1; SMN2GCKALDH1A1RPS6KB2 | |
| SCHEMBL5418202 | 0.75 | HRH3 (0.44) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | HRH3 468/4885SMN1; SMN2 3016/4885GCK 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.